The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying antirheumatic drug (DMARD) apremilast (AP; Otesla®) in patients with active psoriatic arthritis (PsA) at 14 and 26 weeks after starting the treatment and to identify the place of AP in the combination...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Russo |
| Argitaratua: |
IMA PRESS LLC
2019-07-01
|
| Saila: | Научно-практическая ревматология |
| Gaiak: | |
| Sarrera elektronikoa: | https://rsp.mediar-press.net/rsp/article/view/2730 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|